Predictive value of breast cancer molecular subtypes in Chinese patients with four or more positive nodes after postmastectomy radiotherapy

Breast

Volumn 21, Issue 5, 2012, Pages 657-661

  Wu, San Gang ^a   He, Zhen Yu ^b   Li, Qun ^b   Li, Feng Yan ^b   Lin, Qin ^a   Lin, Huan Xin ^b   Guan, Xun Xing ^b  

^a THE FIRST AFFILIATED HOSPITAL OF XIAMEN UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

Biological analysis of tumor markers; Breast neoplasms therapy; Estrogen receptors; Her 2 receptors; Progesterone receptors; Treatment outcome

Indexed keywords

ANTHRACYCLINE; AROMATASE INHIBITOR; CYCLOPHOSPHAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FLUOROURACIL; GOSERELIN; METHOTREXATE; PROGESTERONE RECEPTOR; TAMOXIFEN; TAXANE DERIVATIVE;

ADJUVANT THERAPY; ADULT; ARTICLE; BREAST CANCER; CANCER CLASSIFICATION; CANCER MORTALITY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RELAPSE; CHINESE; CONTROLLED STUDY; DISTANT METASTASIS FREE SURVIVAL; FEMALE; FOLLOW UP; HUMAN; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MASTECTOMY; OUTCOME ASSESSMENT; POSTMASTECTOMY RADIOTHERAPY; POSTOPERATIVE CARE; PREDICTIVE VALUE; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; RETROSPECTIVE STUDY;

EID: 84865993855     PISSN: 09609776     EISSN: 15323080     Source Type: Journal    
DOI: 10.1016/j.breast.2012.07.004     Document Type: Article

References (24)

1. Goldhirsch A., Wood W.C., Gelber R.D., Coates A.S., Thurlimann B., Senn H.J. Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol 2007, 18(7):1133-1144. 10.1093/annonc/mdm271.
2. Overgaard M., Hansen P.S., Overgaard J., Rose C., Andersson M., Bach F., et al. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish breast cancer cooperative group 82b trial. N Engl J Med 1997, 337(14):949-955. 10.1056/nejm199710023371401.
3. Overgaard M., Jensen M.B., Overgaard J., Hansen P.S., Rose C., Andersson M., et al. Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish breast cancer cooperative group DBCG 82c randomised trial. Lancet 1999, 353(9165):1641-1648. 10.1016/s0140-6736(98)09201-0.
4. Ragaz J., Olivotto I.A., Spinelli J.J., Phillips N., Jackson S.M., Wilson K.S., et al. Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial. J Natl Cancer Inst 2005, 97(2):116-126. 10.1093/jnci/djh297.
5. Sorlie T., Perou C.M., Tibshirani R., Aas T., Geisler S., Johnsen H., et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U.S.A. 2001, 98(19):10869-10874. 10.1073/pnas.191367098.
6. Carey L.A., Perou C.M., Livasy C.A., Dressler L.G., Cowan D., Conway K., et al. Race, breast cancer subtypes, and survival in the Carolina breast cancer study. JAMA 2006, 295(21):2492-2502. 10.1001/jama.295.21.2492.
7. Sotiriou C., Neo S.Y., McShane L.M., Korn E.L., Long P.M., Jazaeri A., et al. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci U.S.A 2003, 100(18):10393-10398. 10.1073/pnas.1732912100.
8. Martin M., Rodriguez-Lescure A., Ruiz A., Alba E., Calvo L., Ruiz-Borrego M., et al. Molecular predictors of efficacy of adjuvant weekly paclitaxel in early breast cancer. Breast Cancer Res Treat 2010, 123(1):149-157. 10.1007/s10549-009-0663-z.
9. Hugh J., Hanson J., Cheang M.C., Nielsen T.O., Perou C.M., Dumontet C., et al. Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial. J Clin Oncol 2009, 27(8):1168-1176. 10.1200/jco.2008.18.1024.
10. Rouzier R., Perou C.M., Symmans W.F., Ibrahim N., Cristofanilli M., Anderson K., et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 2005, 11(16):5678-5685. 10.1158/1078-0432.ccr-04-2421.
11. Yin W.J., Lu J.S., Di G.H., Lin Y.P., Zhou L.H., Liu G.Y., et al. Clinicopathological features of the triple-negative tumors in Chinese breast cancer patients. Breast Cancer Res Treat 2009, 115(2):325-333. 10.1007/s10549-008-0096-0.
12. Greene FL, Page DL, Fleming ID, Fritz AG, Balch CM, Haller DG, et al. AJCC cancer staging manual 2006, 6th ed.
13. Jacobs T.W., Gown A.M., Yaziji H., Barnes M.J., Schnitt S.J. Specificity of Hercep test in determining HER-2/neu status of breast cancers using the United States food and drug administration-approved scoring system. J Clin Oncol 1999, 17(7):1983-1987.
14. Kyndi M., Sorensen F.B., Knudsen H., Overgaard M., Nielsen H.M., Overgaard J. Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish breast cancer cooperative group. J Clin Oncol 2008, 26(9):1419-1426. 10.1200/jco.2007.14.5565.
15. Wang S.L., Li Y.X., Song Y.W., Wang W.H., Jin J., Liu Y.P., et al. Triple-negative or HER2-positive status predicts higher rates of locoregional recurrence in node-positive breast cancer patients after mastectomy. Int J Radiat Oncol Biol Phys 2011, 80(4):1095-1101. 10.1016/j.ijrobp.2010.03.038.
16. Kim R.G., Kim E.K., Kim H.A., Koh J.S., Kim M.S., Kim K.I., et al. Prognostic significance of molecular subtype in T1N0M0 breast cancer: Korean experience. Eur J Surg Oncol 2011, 37(7):629-634. 10.1016/j.ejso.2011.04.014.
17. Nguyen P.L., Taghian A.G., Katz M.S., Niemierko A., Abi Raad R.F., Boon W.L., et al. Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy. J Clin Oncol 2008, 26(14):2373-2378. 10.1200/jco.2007.14.4287.
18. Panoff J.E., Hurley J., Takita C., Reis I.M., Zhao W., Sujoy V., et al. Risk of locoregional recurrence by receptor status in breast cancer patients receiving modern systemic therapy and post-mastectomy radiation. Breast Cancer Res Treat 2011, 128(3):899-906. 10.1007/s10549-011-1495-1.
19. Nielsen T.O., Hsu F.D., Jensen K., Cheang M., Karaca G., Hu Z., et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 2004, 10(16):5367-5374. 10.1158/1078-0432.ccr-04-0220.
20. Rakha E.A., El-Sayed M.E., Green A.R., Lee A.H., Robertson J.F., Ellis I.O. Prognostic markers in triple-negative breast cancer. Cancer 2007, 109(1):25-32. 10.1002/cncr.22381.
21. Siziopikou K.P., Cobleigh M. The basal subtype of breast carcinomas may represent the group of breast tumors that could benefit from EGFR-targeted therapies. Breast 2007, 16(1):104-107. 10.1016/j.breast.2006.09.003.
22. Liang K., Jin W., Knuefermann C., Schmidt M., Mills G.B., Ang K.K., et al. Targeting the phosphatidylinositol 3-kinase/Akt pathway for enhancing breast cancer cells to radiotherapy. Mol Cancer Ther 2003, 2(4):353-360.
23. Wollman R., Yahalom J., Maxy R., Pinto J., Fuks Z. Effect of epidermal growth factor on the growth and radiation sensitivity of human breast cancer cells in vitro. Int J Radiat Oncol Biol Phys 1994, 30(1):91-98.
24. Dahabreh I.J., Linardou H., Siannis F., Fountzilas G., Murray S. Trastuzumab in the adjuvant treatment of early-stage breast cancer: a systematic review and meta-analysis of randomized controlled trials. Oncologist 2008, 13(6):620-630. 10.1634/theoncologist.2008-0001.